ASTRIA THERAPEUTICS INC (ATXS) Stock Analyst Ratings
USA - NASDAQ:ATXS - US04635X1028 - Common Stock
12.47 USD
-0.07 (-0.56%)
12.3 USD
-0.17 (-1.36%)
ChartMill assigns a Buy % Consensus number of 85% to ATXS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 30.37. This target is 143.57% above the current price.
ATXS was analyzed by 15 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about ATXS.
In the previous month the buy percentage consensus was at a similar level.
ATXS was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-16 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-10-15 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2025-10-15 | Wedbush | Downgrade | Outperform -> Neutral |
| 2025-10-14 | Jefferies | Downgrade | Buy -> Hold |
| 2025-09-17 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-09-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-13 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-04-29 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-03-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-03-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-03 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-31 | JMP Securities | Initiate | Market Outperform |
| 2025-01-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-08-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-29 | TD Cowen | Initiate | Buy |
| 2024-05-21 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-05-10 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-05-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
ASTRIA THERAPEUTICS INC / ATXS FAQ
What do analysts expect the price target to be for ASTRIA THERAPEUTICS INC (ATXS)?
15 analysts have analysed ATXS and the average price target is 30.37 USD. This implies a price increase of 143.57% is expected in the next year compared to the current price of 12.47.
What is the consensus rating for ASTRIA THERAPEUTICS INC (ATXS) stock?
The consensus rating for ASTRIA THERAPEUTICS INC (ATXS) is 85.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for ASTRIA THERAPEUTICS INC stock?
The number of analysts covering ASTRIA THERAPEUTICS INC (ATXS) is 15.